Well, good up-side action at the close.<g>
Part of that could be due to the following:
SOURCE: Canada's Business Report; Biomira Inc.
On today's Canada's Business Report... Biomira, the cancer vaccine people.
TORONTO, May 18 /CNW/ - Dr. Alex McPherson, President and Chief Executive Officer of Biomira Inc. is live on Canada's Business Report today on the Company In Profile feature.
McPherson talks with host Robert Graham about the test results for Biomira's colon cancer vaccine, their collaboration with Merck KGaA, and their finances.
McPherson will also provide updates on research on breast and lung cancer vaccines.
Biomira is a biotechnology company specializing in the development of innovative therapeutic approaches to cancer management.
The Company completed enrolment of 1,030 patients in a multinational Phase III trial with THERATOPE® vaccine in combination with Corixa's ENHANZYN(TM) adjuvant.
As well, Biomira is developing a portfolio of complementary vaccine candidates, including BLP25 for non-small cell lung cancer, now in Phase IIb trials.
The commitment to the treatment of cancer currently focuses on the development of synthetic vaccines and novel strategies for cancer immunotherapy.
Executive produced by Canada NewsWire, Canada's Business Report provides listeners with the most comprehensive Canadian market information and analysis on radio.
The half-hour weekday program airs on 15 stations coast to coast including CFRB 1010 in Toronto and can be heard live on the Canada NewsWire Web site beginning at 5:06 p.m. (ET) at www.newswire.ca/cbr.
Bernard
P.S.: I haven't been able to get a fill on my order to buy at 6.75 as yet.<g> |
